Radium-223 dichloride

BNF:

not listed

Status:

Red

Decision Date:

October 2016

Comments

RED^1,2,3: NICE TA 412 for treating hormone-relapsed prostate cancer with bone metastases. (Decision date - October 2016). This guidance replaces NICE TA376

Red Drug Classifications

• 1: Requiring specialist assessment to enable patient selection, initiation and ongoing treating
• 2: Requiring long term on-going monitoring of efficacy by a specialist and not suitable for shared care
• 3: Requiring long term on-going monitoring of toxicity by a specialist (either because of difficulty in recognising side effects or high cost of investigations to identify toxicity)

search again